RSNA 2018

Abstract Archives of the RSNA, 2018


SSG03-06

Deep Learning for Rule-Out of Unnecessary Follow-Up in Patients with Incidentally Detected, Indeterminate Pulmonary Nodules: Results on an Independent Dataset

Tuesday, Nov. 27 11:20AM - 11:30AM Room: S504AB



Participants
Heiko Peschl, Oxford, United Kingdom (Abstract Co-Author) Nothing to Disclose
Carlos Arteta, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd
Lyndsey C. Pickup, MEng, DPhil, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd; Co-founder, Optellum Ltd
Maria Tsakok, Oxford, United Kingdom (Abstract Co-Author) Nothing to Disclose
Sarim Ather, MBChB, PhD, Oxford, United Kingdom (Presenter) Nothing to Disclose
Samia Hussain, Oxford, United Kingdom (Abstract Co-Author) Nothing to Disclose
William Hickes, MSc, Oxford, United Kingdom (Abstract Co-Author) Research Grant, Mirada Medical Ltd
Petr Novotny, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd
Catarina Santos, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd
Emily Fay, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd
Jerome M. Declerck, PhD, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd; Co-founder, Optellum Ltd
Vaclav Potesil, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd Founder, Optellum Ltd Employee, Hocoma AG
Timor Kadir, Oxford, United Kingdom (Abstract Co-Author) Employee, Optellum Ltd;
Fergus V. Gleeson, MBBS, Oxford, United Kingdom (Abstract Co-Author) Consultant, Alliance Medical Limited; Consultant, Blue Earth Diagnostics Ltd; Consultant, Polarean, Inc

For information about this presentation, contact:

Heiko.Peschl@ouh.nhs.uk

PURPOSE

To assess the follow-up rule-out accuracy of a convolutional neural network (CNN) in patients with incidentally detected, indeterminate pulmonary nodules in a multi-site, heterogeneous population.

METHOD AND MATERIALS

The US National Lung Screening Trial (NLST) dataset was manually curated and used to create a training set: each reported nodule and cancer was located, contoured and diagnostically characterised (9310 benign nodule patients; 1058 cancer patients). All patients with solid and semi-solid nodules of 6mm and above, where benign nodules and cancers could be confidently identified by clinicians (5972 patients, of which 575 were cancer patients), were selected. A CNN was trained using Deep Learning and three thresholds for benign rule-out were calculated at three levels of sensitivity: 100%, 99.5% and 99%. An independent dataset of patients with incidentally detected indeterminate pulmonary nodules was retrospectively collected from a tertiary referral centre and surrounding hospitals in the UK with a heterogeneous mix of scan parameters, manufacturers and clinical indications (610 patients, 698 nodules, 5-15mm). Diagnosis was established according to British Thoracic Society guidelines (2015). The dataset contained 50 cancers from 47 patients (7% of all nodules). Performance was evaluated by measuring the specificity at the three benign rule-out thresholds; i.e. to measure the proportion of benign nodules correctly stratified while missing no or few cancers. Overall Area-Under-the-ROC-Curve analysis (AUC) was also calculated.

RESULTS

The specificity (sensitivity) was 24% (100%), 24% (100%) and 48.6% (100%) at the three thresholds respectively. AUC was 0.93 (95%CI = 0.90-0.96).

CONCLUSION

On this independent dataset, the CNN was able to correctly classify just under half of the benign nodules whilst not misclassifying any cancers.

CLINICAL RELEVANCE/APPLICATION

Our work shows the potential of CNNs in ruling out benign pulmonary nodules and therefore reducing the need for follow up scans in a large number of patients.